Skip to main content
. Author manuscript; available in PMC: 2012 Apr 15.
Published in final edited form as: Int J Cancer. 2011 Apr 15;128(8):1836–1842. doi: 10.1002/ijc.25524

Figure 3. TFII-I protein or phosphotyrosyl levels are not sufficient to induce or suppress oncogenic transformation.

Figure 3

Phase contrast images of NIH3T3 and Src/3T3 stable transfectants expressing vector, GST-fused WT- or Y248/249F (“Y->F”)-TFII-I, or TFII-I siRNA.